Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-Time text messages from your fitness tracker: a new way to fight diabetes?

NCT ID NCT05351359

Disease control Sponsor: Charles University, Czech Republic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether a mobile health system that sends real-time text messages—prompting users to take a walk or stand up after sitting too long—can increase physical activity in people with prediabetes or type 2 diabetes. Participants receive a Fitbit tracker and brief advice from their doctor. Half also get the text-message coaching and monthly phone calls for six months. The study measures changes in daily step count, blood sugar, and other health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a mobile health (mHealth) system that sends real-time text messages based on data from a Fitbit wearable tracker
What this could lead to
If effective, this approach could offer a practical, low-cost way for doctors to help patients with prediabetes or type 2 diabetes increase daily activity and improve health.
What could go wrong
The trial is relatively small and relies on participants consistently using the technology. The effect on long-term health outcomes like blood sugar control remains to be seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

343 people

The number who actually took part.

Started

Apr 2022

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of prediabetes or T2DM according to the Czech guidelines for GPs on diabetes mellitus1 and prediabetes2, i.e. fasting plasma glucose 5.6-6.9 mmol/l, or 2-h plasma glucose of 7.8-11.0 mmol/l after ingestion of 75 g of oral glucose load for the diagnosis of prediabetes, and fasting plasma glucose ≥ 7.0 mmol/l, or 2-h plasma glucose ≥ 11.1 mmol/l after ingestion of 75 g of the oral glucose load for the diagnosis of T2DM * Age 18 years or older. * Registered at a participating general practice. * Regular users of a smartphone and willing to use it as part of the study. * Written informed consent obtained before any assessment related to the study. Exclusion Criteria: * unable to walk * pregnancy * taking insulin * living in a residential or nursing care home * co-morbid conditions that would affect their adherence to the trial procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes Type 2 diabetes

Contacts and locations

Locations

  • Institute of General Practice

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.